Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levomilnacipran ER Relapse Prevention in MDD
NCT02288325Phase 4Completed
- Sponsor
- Forest Laboratories
- Start
- Nov 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of levomilnacipran in major depressive disorder (MDD) (3 arms), sponsored by Forest Laboratories. Primary endpoint: Time to First Relapse During the Double-Blind Treatment Period at 26 weeks. Started Nov 2014; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02288325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288325.